

DAFTAR PUSTAKA

1. Khot WY, Nadkar MY. The 2019 novel coronavirus outbreak – a global threat. *J Assoc physicians India*. 2020; 68 (3):67-71
2. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A dkk. In Burhan E, Susanto AD, Isbaniyah F editors. Pedoman tatalaksana COVID-19 edisi 3. 3th ed. Pedoman tatalaksana COVID-19. Jakarta; 2020. h.1-10
3. Wang J, Jiang M, Chen X, Montaner L. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection : Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *Journal of Leukocyte Biology*. 2020; 108: 17-41.
4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N dkk. Complex Immune Dysregulation in COVID-19 patients with Severe Respiratory Failure. *Cell Host & microbe*. 2020; 27 (6): 992-1000
5. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y dkk. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol*. 2020; 127 (104370): 1-5
6. Gubernatorova E.O, Gorshkova E.A, Polinova A.I, Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. *Cytokine Growth Factor Rev*. 2020;53(1):13–24
7. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, Bergwelt-Baildon M dkk. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol*. 2020; 146 (1): 128-36
8. Aziz M, Fatima R, Assaly R. Elevated Interleukin-6 and severe COVID-19: A meta-analysis. *J Med Virol*. 2020; 92 : 2283-85
9. Wang Y, Sibaii F, Lee K, J. Gill M, L. Hatch J. Level of IL-6 predicts Respiratory Failure in Hospitalized Symptomatic COVID-19 Patients. *medRxiv J*. 2021;1(165):1–13
10. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, dkk. Clinical characteristic of 82 death cases with COVID-19. *Plos one*. 2020: 15(7):e0235458:1-13

11. Marfilan. D.R, Hisbullah, Musba A.M, Salam S.H, Muchtar F, Nurdin H. The correlation of Transaminase Enzyme on the Prognosis of COVID-19 patients in the ICU infection Center Dr. Wahidin Sudirohusodo General Hospital Makassar. *Britain International of Exact Sciences Journal*.3(6).1-9
12. Bourgonje, A.R, Abdulle A.E, Timens W, Hillebrands J.L, Navis G.J, Gordijn S.J dkk. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *Journal of Pathology*. 2020; 251 (3). 228-48
13. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int Off J Int Assoc Study Liver*. 2020 May;40(5):998–1004
14. Zhang Chao, Shi Lei, Wang FS. Liver injury in COVID-19 : management and challenges. *Lancet*. 2020 ; 5: 428-9
15. Zhao X-Y, Xu X-X, Yin H-S, Hu Q-M, Xiong T, Tang Y-Y, dkk. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan are of Hubei province, China: a retrospective study. *BMC infectious diseases*. 2020: 20(311): 1-8
16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y dkk. Epidemiological and clinical characteristic of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020; 395: 507-13
17. McConnell J.M, Kawaguchi, Kondo R, Sonzogni A, Licini L, Valle C dkk. Liver injury in COVID-19 and IL-6 trans-signaling induced endotheliopathy. *Journal of Hepatology*. 2021; 75 : 647-58
18. Da B.L, Kushner T, Halabi M.E, Paka P, Khalid M, Uberoi A dkk. Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6. *Hepatology Communications*. 2021; 5 (2) : 177-88
19. Ponziani FR, Nesci A, Zompo F, Santopaolo F, Pompili M, Gasbarrini A. Correlation between Liver function Test Abnormalities and Interleukin-6 serum Levels in patients with SARS-CoV-2 infection. *Gastroenterology*. 2020 ; 160: 1891-92

20. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. *PLoS Pathog.* 2020; 16 (5): 1-24
21. Korsman SNJ, Zyl GU, Nutt L, Andersson MI, Preiser W. Human Coronavirus. *Virology.* 2012; 94-5
22. Wiersinga W.J, Rhodes A, Cheng A.C, Peacock S.J. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). *JAMA.* 2020; 324 (8):782-793
23. Cevik M, Kuppali K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. Clinical update. *BMJ.* 2020; 37: p1-6
24. Sabaka P, Koščálová A, Straka I, Hodosy J, Lipták R, Kmotorková B, dkk. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. *BMC Infect Dis.* 2021;21(1):4–11
25. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings ini 919 patients. *Am J Roentgenol.* 2020; 215 (1): 87-93
26. Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. *Arch Pharm Res.* 2021;44(1):99–116
27. Hussain M, Syed SK, Fatima M, Shaukat S, Saadullah M, Alqahtani AM, dkk. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. *J Inflamm Res.* 2021;14(8):7225–42
28. Stephen-Victor E, Das M, Karnam A, Pitard B, Gautier JF, Bayry J. Potential of regulatory T-cell-based therapies in the management of severe COVID-19. *Eur Respir J.* 2020;56(3):3–6
29. Melo AKG, Milby KM, Caparroz ALMA, Pinto ACPN, Santos RRP, Rocha AP, dkk. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis. *PLoS One.* 2021;16(6 June):1–21
30. Ramatillah DL, Gan SH, Pratiwy I, Sulaiman SAS, Jaber AAS, Jusnita N, dkk. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. *PLoS One.* 2022;17(1 1):1–14

31. Tanaka T, Narazaki M, Kishimoto T. Il-6 in inflammation, Immunity, And disease. *Cold Spring Harb Perspect Biol.* 2014;6(10):1–16
32. Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, dkk. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Front Immunol.* 2021;12(2):1–10
33. Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup. *N Engl J Med.* 2021;384(16):1564–75
34. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. *Liver Int.* 2021;41(1):20–32
35. Yu D, Du Q, Yan S, Guo XG, He Y, Zhu G, dkk. Liver injury in COVID-19: clinical features and treatment management. *Virology Journal.* 2021;18(121):1–9
36. Kulkarni A V, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, dkk. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Alimentary Pharmacology and Therapeutic.* 2020 : 52: 584-99
37. Bernal-Monterde V, Casas-Deza D, Letona-Giménez L, Llama-Celis N, Calmarza P, Sierra-Gabarda O, dkk. SARS-CoV-2 Infection Induces a Dual Response in Liver Function Tests: Association with Mortality during Hospitalization. *Biomedicines.* 2020; 8 (328) : 1-12
38. Cichoż- Lach H, Michalak A. Liver injury in the era of COVID-19. *World journal of Gastroenterology.* 2021; 27 (5): 377-90
39. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Vol. 40, *Liver international : official journal of the International Association for the Study of the Liver.* United States; 2020. p. 1278–81
40. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Elsevier.* 2020;54(January):62–75
41. Mucha SR, Dugar S, McCrae K, Joseph D, Bartholomew J, Sacha GL, dkk.

- Coagulopathy in COVID-19: Manifestations and management. *Cleve Clin J Med*. 2020 Jul;87(8):461–8
42. Zou Y, Guo H, Zhang Y, Zhang Z, Liu Y, Wang J, dkk. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. *Biosci Trends*. 2020 Sep;14(4):285–9
43. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, dkk. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia : A hospital-based retrospective cohort study. *Lancet Reg Heal – West Pacific*. 2021;9:100108. 1-9
44. Peta sebaran COVID-19/Covid19.go.id (internet). Available from:<https://covid19.go.id/peta-sebaran-covid19>
45. Mardewi IGA, Yustiani NT. Gambaran hasil laboratorium pasien COVID-19 di RSUD Bali Mandara : sebuah studi pendahuluan. *Intisari Sains Medis*. 2021; 12 (1):374-8
46. Liu T, Zhang J, Yang Y, Ma H, Li Z, Yi J dkk. The role of IL-6 in monitoring case of coronavirus disease 2019. *EMBO molecular medicine*. 2020; 12: 1-12
47. Kuehn BM. Global health. Covid-19 in clinicians-more cases in women, more deaths in men. *JAMA - J Am Med Assoc*. 2021;325(7):612
48. Doerre A, Doblhammer G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. *PLoS One*. 2022;17(5):1–20
49. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): A systematic review and meta-analysis. *BMJ Open*. 2020;10(10):1–10
50. Das SK. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). *Indian J Clin Biochem*. 2020;35(4):385–96.
51. Malmgren J, Guo B, Kaplan HG. Continued proportional age shift of confirmed positive COVID-19 incidence over time to children and young adults: Washington State March - August 2020. *PLoS One [Internet]*. 2021;16(3):1–12
52. Yu X, Duan J, Jiang Y, Zhang H. Distinctive trajectories of the COVID-19

- epidemic by age and gender: A retrospective modeling of the epidemic in South Korea. *Int J Infect Dis.* 2020;98:200–5
53. Dhama K, Patel SK, Kumar R, Rana J, Yatoo MI, Kumar A, dkk. Geriatric Population During the COVID-19 Pandemic: Problems, Considerations, Exigencies, and Beyond. *Front Public Heal.* 2020;8(9):1–8
54. Jugler C, Sun H, Chen Q. SARS-CoV-2 spike protein-induced interleukin 6 signaling is blocked by a plant-produced anti-interleukin 6 receptor monoclonal antibody. *Vaccines.* 2021;9(11):1–12
55. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca M V. The role of interleukin 6 during viral infections. *Front Microbiol.* 2019;10(5):6–11
56. Dwi Ananda RY, Nova Kurniati, Harun Hudari, Erial Bahar. Correlation of Interleukin-6 Levels with Clinical Features and Chest X-Ray Imaging in Coronavirus Disease-19 (COVID-19) Patients at Dr. Mohammad Hoesin General Hospital Palembang. *Biosci Med J Biomed Transl Res.* 2022;6(5):1799–805
57. Hwaiz R, Merza M, Hamad B, HamaSalih S. Evaluation of hepatic enzymes activities in COVID-19 patients. *Int Immunopharmacol.* 2021;9(7):107-11
58. Harisha EJ, Gosavi S, Rao AA. Liver function and dysfunction in COVID-19. *Journal of Family Medicine.* 2021;1(2):1-7
59. Sanyaolu A, Okorie C, Marinkovic A, Patidar R. Comorbilidad y su impacto en pacientes con COVID-19. *SN Compr Clin Med.* 2020;2:1069–76
60. Rebello CJ, Kirwan JP, Greenway FL. Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? *Int J Obes.* 2020;44(9):1810–7
61. Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. *BMJ Nutr Prev Heal.* 2022;5(1):10–8
62. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *J Community Empower Heal.* 2020;3(2):77
63. Hernández-Garduño E. Obesity is the comorbidity more strongly associated

- for Covid-19 in Mexico. A case-control study. *Obes Res Clin Pract.* 2020;14(4):375–9
64. Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, dkk. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. *Sci Rep.* 2020;10(1):1–9
 65. Li X, Xu S, Yu M. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *American Academy of Allerg.* 2019;19(2):165–72.
 66. Zhang C, Wu Z, Li W, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19 : interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents.* 2020; 55(5): 1-10
 67. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19 A systematic review and meta-analysis. *Rev Med Viral.* 2020;2(1):1-5
 68. Sanli DET, Altundag A, Kandemirli SG. Relationship between disease severity and serum IL-6 levels in COVID-19 anosmia. *Am J Otolaryngol.* 2021;42(1):1-27
 69. Sun H, Guo P, Zhang L, Wang F. Serum interleukin-6 concentrations and the severity of COVID-19 pneumonia: A retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020. *Med Sci Monit.* 2020;2(6):1–6
 70. Gao Y, Li T, Han M, Li X, Wu D, Xu Y dkk. Diagnostic utility of clinical laboratory data determinations for patient with the severe COVID-19. *Journal of Medical Virology.* 2020;1-6
 71. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. *United European gastroenterology journal.* 2020;8(5): 509-19
 72. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y dkk. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395: 497-506
 73. Boregowda U, Aloysius MM, Perisetti A, Gajendran M, Bansal P, Goyal H. Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis. *Front Med.* 2020;7(7):1–10
 74. Higuera-de la Tijera F, Servín-Caamaño A, Reyes-Herrera D, Flores-López

- A, Robiou-Vivero EJA, Martínez-Rivera F, dkk. Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19. *Liver Res.* 2021;5(1):21–7
75. Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L dkk. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. *Hepatology.* 2020;72 : 389-98
76. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G dkk. Clinical characteristics of 113 deceased patients with Coronavirus disease 2019: retrospective study. *BMJ.* 2020; 368.m1091:1-12
77. Giboney PT. Mildly elevated liver transaminase levels in the Asymptomatic patient. *American family physician.* 2005; 71 (6):1105-10
78. Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR dkk. Acute liver injury in COVID-19 : prevalence and association with clinical outcome in a large U.S cohort. *Hepatology.* 2020 ; 72 : 807-17

